. 2023 Mar 10;12(4):e220455. doi: 10.1530/EC-22-0455
This work is licensed under a Table 1.
Clinical characteristics at baseline and after 24 weeks in men treated with placebo and testosterone replacement therapy.
| Placebo | Testosterone replacement therapy | |||||
|---|---|---|---|---|---|---|
| Variable | Baseline | 24 weeks | P | Baseline | 24 weeks | P |
| N | 20 | 20 | 17 | 17 | ||
| Age (years) | 53 ± 11 | 54 ± 7 | ||||
| Weight (kg) | 98.7 ± 15.5 | 99.7 ± 15.5 | 0.37 | 100.9 ± 13.2 | 104.4 ± 14.1 | <0.01 |
| BMI (kg/m2) | 32.0 ± 4.1 | 32.3 ± 4.0 | 0.56 | 31.3 ± 3.8 | 32.5 ± 4.3 | <0.01 |
| Total fat mass (kg) | 33.2 ± 6.1 | 33.8 ± 6.5 | 0.26 | 33.0 ± 7.5 | 31.6 ± 7.8 | <0.01 |
| Fat percentage (%) | 34.9 ± 2.8 | 35.5 ± 3.4 | 0.24 | 33.8 ± 5.1 | 31.6 ± 4.4 | <0.01 |
| Lean body mass (kg) | 59.7 ± 9.3 | 59.3 ± 9.8 | 0.57 | 61.5 ± 7.7 | 65.2 ± 7.3 | <0.01 |
| Total testosterone (nmol/L)a | 7.4 (5.1; 9.6) | 7.7 (5.2; 8.5) | 0.46 | 6.8 (5.2; 9.5) | 19.4 (14.3; 26.8) | <0.01 |
| Sex hormone-binding globulin (nmol/L)a | 32.2 (24.5; 44.5) | 31.5 (20.7; 51.2) | 0.48 | 41.9 (24.5; 51.7) | 36.9 (24.6; 45.9) | <0.01 |
| Bioavailable testosterone (nmol/L)a | 3.5 (2.1; 4.4) | 3.0 (1.9; 4.1) | 0.40 | 2.7 (2.0; 3.8) | 8.6 (8.1; 12.4) | <0.01 |
| Total cholesterol (mmol/L) | 4.8 ± 1.0 | 4.8 ± 1.2 | 0.71 | 4.5 ± 0.9 | 4.3 ± 0.9 | 0.30 |
| LDL (mmol/L) | 2.8 ± 1.0 | 2.7 ± 1.0 | 0.38 | 2.6 ± 0.8 | 2.5 ± 0.7 | 0.41 |
| Triglycerides (mmol/L)a | 1.6 (1.1; 2.9) | 1.8 (1.2; 3.1) | 0.53 | 1.5 (1.0; 2.2) | 1.8 (1.0; 2.3) | 0.60 |
Data presented as mean ± s.d. were compared at baseline and 24 weeks with a paired t-test. Subjects’ characteristics were previously reported in Glintborg et al (7). aData presented as median (25 and 75 percentiles) were compared with a Wilcoxon test. Significant differences are highlighted in bold. BMI, body mass index; LDL, low-density lipoprotein cholesterol.